Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer

Purpose Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standard of care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, there are no data on this drug in Korean patients.